HIG Capital acquires BioVectra
An affiliate of private equity investment firm HIG Capital (HIG) has completed the acquisition of BioVectra, a contract development and manufacturing organisation (CDMO) of active pharmaceutical ingredients and intermediates. Founded in 1970, BioVectra’s core competencies include microbial fermentation, complex chemistry, high potency, and biologics. They impact the lives of patients